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(Received 13 December 1993; accepted 18 July 1994) Summary &horbar; In order to establish a relationship between the appearance of congenital malformations and the decrease of folic acid in rat mothers and embryos, a folic acid antagonist, pyrimethamine (PY), was administered. On the 12th day of gestation/pregnant rats received an intraperitoneal injection of 12.5, 15.63, 18.75 or 25 mg/kg PY. On the l3th day of gestation folic acid was measured in different maternal and embryonic tissues obtained after surgical hysterectomy of 1 uterine horn. On the 21st day of gestation malformations were studied on live fetuses remaining in the opposite horn. The folate levels were identical in all maternal tissues. The concentration of folic acid significantly decreased (50%) within the embryonic tissues in all PY-treated groups. A decrease of fetal weight occurred in the 18. 75 (Laurence et al, 1980) or artificially induced by a poor maternal diet (Baird etal, 1954; Monie etal, 1954; Monie et al, 1957) (Milunski et al, 1968; Powel and Ekert, 1971; Hill etal, 1974 ; Hanson and Smith, 1975; Jordan etal, 1977; Warkany, 1978; Wilson et al, 1979) .
Pyrimethamine, an antimalarial drug, is highly teratogenic in the rat (Dyban et al, 1976 ; Sullivan and McElhatton, 1977; Tangapregassom et al, 1985; Horvath et al, 1989; Raynaud et al, 1990) . (Compagnon, 1987; Raynaud ei al, 1990 The fetuses were randomly divided into 2 groups. In the first group the fetuses were fixed in 96% ethanol, then stained with alizarin red S and alcian blue (Peters, 1977, modified by Horvath) in order to study skeletal malformations. The fetuses assigned to the second group were fixed in Bouin's fluid and later dissected to allow the study of visceral malformations (Wilson, 1965 (fig 4) .
Several fetuses were polymalformed to such a degree that we decided to establish a scale of seriousness of the malformations (0 to 9 ; table I). ) . Figure 5 shows the relationship between the toxic or teratogenic effect and the fetal individual weight. Independently of the dose administered, no malformed fetus was observed for a fetal weight over 3 g. All control fetuses as well as all the fetuses except 1 from the 12.5 mg/kg PY-treated mothers weighed more than 3 g. A toxic but not teratogenic effect of the drug was noted for normal fetuses weighing less than 3 g. The limit between the toxic and the teratogenic effect clearly appears with the 2 highest doses (18.75 and 25 mg/kg PY). (Compagnon, 1987 (Landon et al, 1975 (Green and Ford, 1984) and guinea-pig (Sweiry and Yudilevitch, 1985) trophoblast microvilli. Landon et al (1975) found a higher concentration of folates in the fetal circulation than in the maternal circulation and inferred that active transport processes are involved.
The degenerative placental changes observed are in good agreement with the histological studies of Johnson et al (1963) . Using 9-methyl-PGA, these authors found slight hemorrhages and vacuolization and pyknosis of giant cells at the maternal-fetal junction in rats. Similar placental and teratogenic effects were obtained by Khera (1992) after administration of valproic acid in rats. These alterations might be responsible for the deficient transfer of folates to the fetus by the FABP. PY is also known to cross the placenta and accumulate in the embryo (Labbé et al, 1988) .
Considering the concentration of folates in the embryonic bodies, statistical analysis indicates that a slight difference exists between the 4 treated groups. This difference could be attributable to the liver differentiation, which takes place between the l0th and 11th days of gestation. The principal site of embryonic DHFR synthesis is of hepatic origin and maximum enzyme activity is observed in 11-day-old embryos. At that time DHFR is very sensitive to PY action: its affinity for the drug is much higher at gestation days 11 and 12 than later (Repin et al, 1972) .
These results confirm previous findings (Raynaud et al, 1990 ). However, we could not find any direct correlation between the decrease of folic acid which occurred with the lowest dose (12.5 mg/kg) and the congenital malformations first observed with a higher dose (18.75 mg/kg). Which factor could be responsible for the shifting between these 2 results? First, folic acid assay method could be involved. Folic acid is assayed as mono-and oligoglutamates after hydrolysis by endogenous conjugase. Biologically active conjugates are polyglutamates and the technique does not take into account active forms nor their cell availability. Secondly, the 2 lowest doses (12.5 and 15.63 mg/kg) administered had no effect on organogenesis because the threshold of teratogenic sensitivity might occur with higher doses.
